[HTML] mdpi.com

[HTML][HTML] Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford, AB Smith… - Journal of clinical …, 2020 - mdpi.com
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …
被引用次数：31 相关文章

Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford, AB Smith… - Journal of Clinical …, 2020 - search.proquest.com
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …

Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma.

FA Lynch, L Katona, M Jefford… - Journal of Clinical …, 2020 - search.ebscohost.com
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …

Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …
[PDF] semanticscholar.org

[PDF][PDF] Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford, AB Smith… - J. Clin …, 2020 - pdfs.semanticscholar.org
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …
[HTML] nih.gov

[HTML][HTML] Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford, AB Smith… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …

Feasibility and acceptability of Fear-Less: a stepped-care program to manage fear of cancer recurrence in people with metastatic melanoma

FA Lynch, L Katona, M Jefford, AB Smith, J Shaw… - 2020 - opal.latrobe.edu.au
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …

Feasibility and acceptability of Fear-Less: a stepped-care program to manage fear of cancer recurrence in people with metastatic melanoma

FA Lynch, L Katona, M Jefford, A Ben Smith, J Shaw… - 2020 - dro.deakin.edu.au
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …
[PDF] unimelb.edu.au

[PDF][PDF] Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford, AB Smith… - J. Clin …, 2020 - minerva-access.unimelb.edu.au
Immunotherapies and targeted therapies have revolutionised treatment of metastatic
melanoma and improved survival rates. However, survivors treated with novel therapies are …
[HTML] mdpi.com

[HTML][HTML] Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

FA Lynch, L Katona, M Jefford, AB Smith, J Shaw… - mdpi.com
Background: Chronic hepatitis C virus (HCV) infections are causally linked with metabolic
comorbidities such as insulin resistance, hepatic steatosis, and dyslipidemia. However, the …